New treatment that enhances product choice is ‘spot-on’

Nov 13, 2017

Vets have another tool in their kit to treat fleas and ticks with the release of Bravecto Spot-on for Dogs. MSD Animal Health has added to its existing range with the new product, which offers 12-week flea and tick protection, and provides vets and owners with more choice when it comes to treatment. The complementary product joins the Bravecto Dog Chew and follows swiftly on the heels of the launch of Bravecto Spot-on for Cats. MSD marketing manager Amanda Melvin said: “Our research has shown convenience is the key to improving compliance and successfully eradicating fleas and ticks. “By offering a new formulation of a 12-week treatment, Bravecto Spot-on for Dogs further increases the opportunity. It improves the choice for vets and pet owners, depending on the client’s lifestyle and type of dog.” The product also affords vets the opportunity to raise the topic of fleas and ticks with clients that have been more reluctant to use existing products, Ms Melvin added. A range of materials for practice staff and... ...

Read More

Pimobendan study outcome – a ‘revolution’ for vet cardiology

Nov 13, 2017

A product that delays onset of congestive heart failure (CHF) in dogs by 15 months offers a “paradigm shift” in the way vets diagnose and treat myxomatous mitral valve disease (MMVD). Boehringer Ingelheim, the company behind pimobendan drug Vetmedin, cautiously estimated 7.5% of all dogs would suffer heart disease in their lifetimes, with MMVD its most prevalent form. Vetmedin was already licensed for the treatment of canine CHF from dilated cardiomyopathy or valvular insufficiency, as well as for treatment of cardiomyopathy in the preclinical stage in Dobermann pinschers. However, following the largest clinical trial in veterinary cardiology, the product can now be used by vets to treat the preclinical stage of MMVD, delaying onset of the clinical symptoms of heart failure. At an official launch for the European veterinary press, held in Frankfurt and attended by Veterinary Times, it was noted up to 40 million dogs worldwide could now benefit with treatment from pimobendan. The evaluation of pimobendan in dogs with cardiomegaly (EPIC) study set out to analyse whether long-term... ...

Read More